Lymphatic Mapping Establishes the Role of BRAF Gene Mutation in Papillary Thyroid Carcinoma

Objective:To define the role of BRAF gene mutation in the progression of papillary thyroid carcinoma. Summary Background Data:BRAF gene mutation is frequently detected in papillary thyroid carcinoma. Its role in pathogenesis or progression is under investigation. Methods:Patients who underwent thyroidectomy and sentinel lymph node biopsy for papillary thyroid cancer were accrued. BRAF mutation was assessed in primary tumors and matched sentinel lymph nodes by a quantitative real-time PCR assay. Results:Tissue specimens from 103 consecutive patients were evaluated. BRAF mutation of the primary tumor was detected in 34 (33%) patients. In 26 of 34 (76%) patients with BRAF mutation, concomitant lymph node metastasis was detected. On the contrary, in 69 patients with BRAF mutation-negative primary tumors, only 12 (17%) patients had lymph node metastasis (&khgr;2, P < 0.0001). BRAF mutation was detected in 20 of 26 (77%) lymph node metastases matched to BRAF mutation-positive primary tumors; it was not detected in lymph node metastases matched to BRAF mutation-negative primary tumors. Univariate analysis identified age, stage, tumor size, and BRAF mutation as prognostic factors for lymph node metastasis. In multivariate analysis, only BRAF mutation remained a significant prognostic factor for lymph node metastasis (odds ratio = 10.8, 95% confidence interval, 3.5–34.0, P < 0.0001). Conclusions:BRAF mutation may be a key genetic factor for the metastatic progression of papillary thyroid carcinoma. The study demonstrates that this gene mutation is a significant risk factor for locoregional lymph node metastasis and has potential utility as a surrogate marker.

[1]  M. Nikiforova,et al.  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[2]  D. Johnston,et al.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. , 1992, The Journal of clinical endocrinology and metabolism.

[3]  W. S. Morgan,et al.  Cancer of the thyroid. , 1954, The Journal of clinical endocrinology and metabolism.

[4]  R. Turner,et al.  Peptide nucleic acid clamp PCR: A novel K‐ras mutation detection assay for colorectal cancer micrometastases in lymph nodes , 2004, International journal of cancer.

[5]  M. Kruhøffer,et al.  The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. , 2005, The Journal of clinical investigation.

[6]  P. Gattuso,et al.  Genomic DNA Extraction and PCR Amplification of Exon 15 of the BRAF Gene and Exons 1 and 2 of the NRAS Gene , 2003 .

[7]  V. Trovisco,et al.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC , 2003, Oncogene.

[8]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[9]  O. Clark,et al.  Papillary thyroid cancer: Surgical management of lymph node metastases , 2005, Current treatment options in oncology.

[10]  D. Morton,et al.  Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas , 2004, Clinical Cancer Research.

[11]  A. Giuliano,et al.  Sentinel lymphadenectomy in thyroid malignant neoplasms. , 1998, Archives of surgery.

[12]  P. Ladenson,et al.  Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. , 2005, The New England journal of medicine.

[13]  Guojun Wu,et al.  High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. , 2005, The Journal of clinical endocrinology and metabolism.

[14]  E. Kimura,et al.  Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched‐lymph node metastasis reveals a new mutation in metastasis , 2005, Clinical endocrinology.

[15]  J. Fagin,et al.  Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. , 2005, Cancer research.

[16]  H. Namba,et al.  Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.

[17]  M. van Glabbeke,et al.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. , 1979, European journal of cancer.

[18]  Mathew J Garnett,et al.  Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.

[19]  T. Chow,et al.  Sentinel lymph node dissection in papillary thyroid carcinoma , 2004, ANZ journal of surgery.

[20]  B. Cady.  Our ames is true: How an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer , 1997 .

[21]  E. Bergstralh,et al.  Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. , 1993, Surgery.

[22]  P. Bartenstein,et al.  Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. , 2003, Thyroid : official journal of the American Thyroid Association.

[23]  Alex Toftgaard Nielsen,et al.  Single nucleotide polymorphism genotyping using locked nucleic acid (LNA™) , 2003, Expert review of molecular diagnostics.

[24]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[25]  K. Czene,et al.  BRAF mutations in metastatic melanoma: a possible association with clinical outcome. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  J. Shah,et al.  Intermediate-risk group for differentiated carcinoma of thyroid. , 1994, Surgery.

[27]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[28]  R. Hruban,et al.  BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. , 2003, The American journal of pathology.

[29]  A. Gamboa-Domínguez,et al.  Accuracy of sentinel lymph node in papillary thyroid carcinoma. , 2001, Surgery.

[30]  Meenhard Herlyn,et al.  BRAF as a potential therapeutic target in melanoma and other malignancies. , 2003, Cancer cell.

[31]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[32]  P. Ladenson,et al.  BRAF mutation in papillary thyroid carcinoma. , 2003, Journal of the National Cancer Institute.

[33]  D. Morton,et al.  Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients , 2004, Oncogene.

[34]  M. Noguchi,et al.  Intraoperative lymphatic mapping and sentinel lymph node biopsy in patients with papillary carcinoma of the thyroid gland. , 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[35]  B. Cady,et al.  An expanded view of risk-group definition in differentiated thyroid carcinoma. , 1988, Surgery.

[36]  C. Mol,et al.  Switching on kinases: oncogenic activation of BRAF and the PDGFR family , 2004, Nature Reviews Cancer.

[37]  S. Berkheiser.  Cancer of the thyroid. , 1953, Guthrie Clinic bulletin.

[38]  J. Fagin,et al.  Apoptosis , Dedifferentiation , and Chromosomal Instability in Thyroid PCCL 3 Cells , 2005 .

[39]  R. Nenkov,et al.  [Sentinel lymph node biopsy in patients with papillary thyroid carcinoma]. , 2006, Khirurgiia.

[40]  M. Catarci,et al.  Preoperative lymphoscintigraphy and sentinel lymph node biopsy in papillary thyroid cancer. A pilot study , 2001, Journal of surgical oncology.